Dr. Rebecca Previs reviews first line treatment options for patients with advanced ovarian cancer.
Ovarian Cancer: Frontline Therapy
An expert in gynecologic oncology talks about the role of bevacizumab in the front-line management of advanced ovarian cancer.
Dr. Rebecca Previs explains the importance of somatic and germline testing in guiding first line treatment selection in women with advanced ovarian cancer.
An expert oncologist reviews therapeutic options for front line maintenance in advanced ovarian cancer.
Dr. Rebecca Previs discusses the role of PARP inhibitors in first line maintenance therapy in advanced ovarian cancer.
Dr. Rebecca Previs talks about when first line maintenance therapy is appropriate and which patients should be presented with this option.
An expert in ovarian cancer describes how initial first line therapy impacts first line maintenance options.
Dr. Rebecca Previs shares data on some exiting emerging therapies in the front line setting for patients with advanced ovarian cancer.
This article reviews emerging evidence on PARP inhibitors as first-line maintenance treatment options after chemotherapy and features expert insights from Rebecca Previs, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
3
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
4
TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)
5